title: Thrombocytopenia in children infected with human immunodeficiency virus: long-term follow-up and therapeutic considerations.
abstract: Among 180 children infected with human immunodeficiency virus (HIV-1), 14 (8%) developed thrombocytopenia during the course of the disease and have been followed for an average period of 18.8 months. Eight of 14 patients had clinical signs of bleeding. Increased levels of anti-platelet IgG antibodies were detected in 86% of patients tested and did not correlate with severity of disease. Eight patients were treated initially with intravenous immunoglobulins (IVIG) and responded with a transient increase in the platelet count of at least 30 x 10(9)/L. Sustained remission could not be achieved in the patients treated with IVIG alone. Corticosteroids were used in 6 patients who became refractory to IVIG and resulted in sustained remission in only one patient. Spontaneous remission of thrombocytopenia occurred in one patient. Ten patients were treated with zidovudine (ZVD) for a period of 3-20 months. Sustained improvement in the platelet counts occurred in only three of the children treated with ZVD.
authors.affiliation: Department of Pediatric Infectious Diseases, New York University Medical Center/Bellevue Medical Center 10016.
authors.forename: M
authors.initials: M
authors.lastname: Rigaud
authors.forename: E
authors.initials: E
authors.lastname: Leibovitz
authors.forename: C S
authors.initials: CS
authors.lastname: Quee
authors.forename: A
authors.initials: A
authors.lastname: Kaul
authors.forename: M
authors.initials: M
authors.lastname: Nardi
authors.forename: H
authors.initials: H
authors.lastname: Pollack
authors.forename: R
authors.initials: R
authors.lastname: Lawrence
authors.forename: D
authors.initials: D
authors.lastname: DiJohn
authors.forename: K
authors.initials: K
authors.lastname: Krasinski
authors.forename: M
authors.initials: M
authors.lastname: Karpatkin
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D016049:Didanosine / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D009518:New York / Q000453:epidemiology; D010976:Platelet Count / Q000187:drug effects; D013921:Thrombocytopenia / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D016756:Immunoglobulins, Intravenous; D015215:Zidovudine; D016049:Didanosine